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Redox reactions are imperative to preserving cellular metabolism yet must be strictly regulated. Imbalances between reactive
oxygen species (ROS) and antioxidants can initiate oxidative stress, which without proper resolve, can manifest into disease.
In type 1 diabetes (T1D), T-cell-mediated autoimmune destruction of pancreatic β-cells is secondary to the primary invasion
of macrophages and dendritic cells (DCs) into the islets. Macrophages/DCs, however, are activated by intercellular ROS from
resident pancreatic phagocytes and intracellular ROS formed after receptor-ligand interactions via redox-dependent transcription
factors such as NF-κB. Activated macrophages/DCs ferry β-cell antigens speciﬁcally to pancreatic lymph nodes, where they trigger
reactive T cells through synapse formation and secretion of proinﬂammatory cytokines and more ROS. ROS generation, therefore,
is pivotal in formulating both innate and adaptive immune responses accountable for islet cell autoimmunity. The importance of
ROS/oxidative stress as well as potential for redox modulation in the context of T1D will be discussed.
1.Introduction
Oxidation-reduction or redox reactions are pivotal to main-
taininglifethroughrespiration,metabolism,andenergysup-
ply. Mitochondria, which are known to be the powerhouses
of the cell, possess the ability to utilize nutrients to generate
energy (redox potential) via the electron transport chain,
which donates electrons to oxygen to yield ATP and H2O
[1, 2].Consequently,oxygenfreeradicals,knownassuperox-
ide (O2
−), are nonenzymatically leaked from the mitochon-
dria and react with other molecules to create reactive oxygen
species (ROS) such as hydrogen peroxide (H2O2), peroxyni-
trite(ONOO−),andhydroxylradical(OH−),allofwhichcan
alter DNA, proteins, carbohydrates, and nucleic acids [3–5]
and may eventually lead to irreversible damage. The inability
of a cell’s antioxidant defenses to overcome oxidative injury
and accretion of severe ROS-mediated damage over time will
eventually lead to cell death [5–7] .I no r d e rt om a i n t a i na
reduced environment, several cellular antioxidant defenses
are in place, including glutathione, glutathione peroxidase,
catalase, and three diﬀerent superoxide dismutase (SOD)
enzymes: SOD1, 2, and 3, located in diﬀerent subcellular
and extracellular locations. A basal level of “accidental”
superoxide is accumulated in healthy individuals [1, 8],
which has been widely hypothesized to be responsible
for aging and the associated pathologies [9–11]. However,
oxidative stress occurs from an imbalance between ROS and
antioxidant actions. During chronic oxidative stress caused
by environmental factors (i.e., UV light, ionizing radiation,
toxic substances), infections, or lack of dietary antioxidants,
an inequity of cellular reducing equivalents capable of
detoxifying the increased burden of ROS has marked eﬀects
on normal cellular processes. However, in times of oxidative
stress, normal cellular respiration is also still functioning,
resulting in dysregulated mitochondrial free radical produc-
tion and disparity between ROS generation and antioxidant2 Clinical and Developmental Immunology
defenses [6, 12]. The combination of stress-induced and
conventional mitochondrial dysfunction can manifest into
diseasestates,includingcancer[13–15],rheumatoidarthritis
[16, 17], neurological disorders [18–21], pulmonary diseases
[22], and type 1 diabetes [23–26].
2. Redox and Inﬂammation
What once was thought to be solely derived from the
mitochondria, reactive oxygen species have now been shown
to be produced by an important family of primarily immune
system-associated enzymes [27–29]. The NADPH oxidase
(NOX) family of enzymes is designed to combine NADPH
and oxygen to actively generate superoxide. Activated phago-
cytes, such as macrophages, monocytes, and dendritic cells
(DCs), as well as neutrophils, form ROS within the phagoso-
malmembraneforeﬃcientkillingofawidearrayofinvading
pathogens [30]. The protection aﬀorded by the phagocytes
is crucial, but not without side eﬀects. Production of highly
permeablereactive oxygen species (i.e., H2O2)ca u s e sl e a k a g e
of these molecules from phagocytes and therefore, unwanted
eﬀects on bystander cells [31, 32]. In an environment
high in oxidative stress, these bystander reactions drive
increased activation of the immune system, cell damage,
and progression to disease. For example, NOX-derived ROS
have been shown to stimulate mitogenic signaling and
proliferation [33, 34], which can have potential deleterious
consequences on the promotion of tumorigenesis [35, 36]
a n di nt h ec o n t e x to fa u t o i m m u n i t y ,c a nl e a dt oTc e l l
expansion [37]. Additionally, H2O2 can augment monocyte
chemokine receptor surface expression critical for migration
to sites of infection and inducing inﬂammation [38]a s
well as can promote VEGF signaling to trigger angiogenesis,
with implications in cancer and tumor progression [39].
Furthermore, ROS generated from both mitochondria and
NADPH oxidase complexes can also act intra-cellularly as
well as inter-cellularly as signal transduction molecules.
Hydrogen peroxide has been suggested to inactivate protein
phosphatases [40], as well as to activate protein tyrosine
kinases [41, 42] and metalloproteases through the oxidation
of critical cysteine residues [43, 44]. Phosphatases such as
SHP-1 serve to decrease inﬂammation by inhibiting tyrosine
kinaseactivity,yetthistypeofregulationislostuponcysteine
oxidation [45–48]. Similarly, latent metalloproteases require
oxidationforactivationand,inthepresenceofhypochlorous
acid (HOCL) and H2O2, secretion of chemotactic mediators
(L-selectin and proinﬂammatory TNFα) is highly increased
[49], thus enhancing inﬂammation. In addition, H2O2 has
been demonstrated to freely cross the plasma membrane
and activate NF-κB, a redox-dependent transcription factor
[50,51].NF-κBplaysamajorroleinimmunitybypromoting
proinﬂammatory cytokine production, cell proliferation,
and inﬂammation. In general, receptor-ligand interactions
are known to generate ROS [52, 53]. In the immune
system speciﬁcally, LPS interaction with Toll-like receptor 4
(TLR4) has been shown to facilitate the binding of TLR4
to NADPH oxidase 4 (Nox4) and subsequently release ROS
[54], resulting in the activation of NF-κB and genera-
tion of proinﬂammatory cytokines IL-1β and TNFα [53].
In a highly oxidized environment, the binding of pathogens
to innate cell receptors can lead to hyperresponsiveness
[55], suggesting inﬂammation is secondary to oxidative
stress [25, 56]. Not only are phagocytic cells critical
for early pathogen recognition through receptor-ligand
interaction, they are also necessary for activation of the
adaptive immune response. Following antigen recognition
by phagocytic antigen-presenting cells (APC), an adaptive
immune response is acquired in secondary lymphoid organs
through synapse formation of APCs with lymphocytes, as
well as from critical innate-derived ROS and third signal
proinﬂammatory cytokines (TNFα,I L - 1 β) enhancing T-
cell activation, proliferation, and eﬀector function [37, 57].
Within this interaction, the H2O2 made by the phagocytes
is able to traverse the synapse and act upon the T cells, at
concentrations ranging from 10–100 μM[ 58, 59], resulting
in a feed-forward mechanism stimulating T-cell-speciﬁc
NF-κB activity and subsequent proinﬂammatory cytokine
production. Similar eﬀects of ROS are also seen on B cells
[60]. Moreover, antigen stimulation of the TCR also drives
endogenous production of H2O2 through the T cell’s own
NOX enzyme [28, 61]. Intracellular H2O2 can then signal
and lead to T-cell proliferation, apoptosis [61, 62], and in
conjunction with proinﬂammatory cytokines, promote T-
cell eﬀector function [37, 52, 63]. Therefore, in the presence
of oxidative stress, an inability to balance the oxidation with
antioxidant enzymes can drive chronic inﬂammation from
both the innate and adaptive arms of the immune response
[64], manifesting into many clinically relevant diseases,
particularly type 1 diabetes.
3. OxidativeStress andType1 Diabetes
Type 1 diabetes or insulin-dependent diabetes mellitus
(T1D) is an autoimmune disorder involving immune-
mediated recognition of islet β-cells by autoreactive T cells,
which leads to the liberation of ROS and proinﬂammatory
cytokines, resulting in the destruction of pancreatic β-cells
in the islets of Langerhans and loss of insulin secretion.
Patients with T1D must constantly prevent hyperglycemia
by administering exogenous insulin or in the situation
of severe hyperglycemic unawareness, by undergoing islet
transplantation. Despite a multitude of eﬀorts in trying to
specify the exact etiology, the cause of T1D is still under
debate. The combinatorial eﬀects of genetic susceptibility,
environmental factors, and dietary deﬁciencies are known to
contribute to disease origin; however, the impact of oxidative
stress in a genetically susceptible individual is of particular
interest. Oxidative stress, as stated above, occurs when the
generation of ROS overcomes the scavenging abilities of
antioxidants. Suchinstancesmaybemediated bygeneticlack
of antioxidant enzymes as well as environmental triggers like
viralinfections.Overall,oxidativestresshasbeenlinkedtoβ-
cell cytotoxicity [65–67]andhasbeensuggestedtoplayarole
inT1Dpathology[68–71].Severalstudiesshowthatthetotal
serum antioxidant status, as measured by urate, Vitamin C,
and total plasma antioxidant levels, of prediabetic and T1D
patients is lower in comparison to age-matched controls [72,
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of proteins and lipids [74]. Other literature illustrates a con-
nection between viruses, ROS production, and type 1 dia-
betesonset.Gambleetal.demonstratedapositivecorrelation
between type 1 diabetes onset and Coxsackie B4 virus infec-
tion through antibody titer measurements [75, 76]. Further-
more, such infections have been shown to cause indirect [77]
and direct β-cell damage [78] and to stimulate the β-cells
into secreting inﬂammatory mediators themselves [79]. ROS
are made following viral infection from activated phagocytes
[80,81],asmentionedpreviously,andworktonotonlycause
cellular injury but also can activate inﬂammatory, redox-
dependent transcription factors, such as NF-κB, perpetu-
ating inﬂammation. Viral-mediated ROS production or a
reduction in antioxidants can have severe consequences as β-
cellsaremorepronetooxidativedamagethanmostothertis-
sues.Theβ-cellmitochondriahaveexceptionallylowlevelsof
glutathione peroxidase, superoxide dismutase, and catalase
activity [24, 82–84]. Because of this low antioxidant defense,
β-cells can be clearly disrupted by oxidative stress and, in
genetically predisposed individuals, results in easy targets for
a subsequent cytokine-mediated autoimmune attack.
Mitochondrial and NOX-derived ROS both have impli-
cations in β-cell destruction and T1D. Increased glucose
causes rapid induction of the tricarboxylic acid (TCA)
cycle within the β-cell mitochondria, which can lead to
augmented ROS production [85]. The superoxide leaked
from mitochondria can then form H2O2 and work to
uncouple glucose metabolism from insulin secretion [86].
Ultimately,highlevelsofmitochondrialROScancauseβ-cell
death [87, 88]. Intriguingly, models of T1D induce disease
by generating toxic amounts of ROS within the islets (i.e.,
streptozotocin and alloxan) [89]. Alloxan is easily taken
up by β-cells [90], where it is reduced into dialuric acid
and subsequently reoxidized to establish a redox cycle [91].
ROS generated by alloxan treatment have been shown to
promote islet β-cell DNA fragmentation, culminating in
cell death [92]. In contrast, an alloxan-resistant strain of
mice, the ALR mouse, shows increased ROS dissipation and
resistancetoisletdestruction[23,93,94],furtherimplicating
the importance of oxidative stress and T1D. Streptozotocin
(STZ), on the other hand, causes β-cell DNA alkylation and
eventually drains the cellular NAD+ and ATP source in an
eﬀort to repair the DNA [95]. Xanthine oxidase is then able
toutilizedephosphorylatedATPasasubstrateforsuperoxide
production [96]. Additionally, STZ metabolism increases the
levels of islet cell nitric oxide (NO) [97], which together with
superoxide can generate peroxynitrite (ONOO−). Detection
of peroxynitrite in prediabetic nonobese diabetic mouse
(NOD) islets suggests importance of this ROS in β-cell death
[71]. Similarly, NOX enzymes have been detected within the
pancreatic β-cells [98, 99]. Hyperglycemia can increase the
assembly of NOX enzymes through its p47phox subunit, and
therefore, enhance superoxide generation [100] and facilitate
β-cell death.
4. Immunology of T1D
Autoimmune diabetes onset is preceded by inﬁltration of
immune cells into the pancreatic islets. Ultimately, a breach
in tolerance to self-antigens allows for autoreactive T cells to
become activated and attack the β-cells, resulting in the loss
of insulin secretion. However, innate immune cells, such as
macrophages and DCs, are of the ﬁrst cells to enter the islets
during insulitis [101, 102]. Although resident macrophages
are present in the pancreas at all times, acquisition of antigen
is required for macrophage activation and the production
of cytokines. As described above, genetic and environmental
factors can lead to cell destruction, releasing β-cell-speciﬁc
antigens as well as ROS [103]. Macrophages will phagocytose
dying β-cells and present antigen in the context of their
MHC molecules. In humans, speciﬁc HLA molecules HLA-
DR3 and DR4 are correlated with a susceptibility to T1D
[103, 104]. Moreover, the ROS created by the initial insult
to the islets are able to stimulate the activation of redox-
dependent NF-κB and other transcription factors within the
macrophages[105].Activatedmacrophagessecreteamixture
of proinﬂammatory cytokines such as TNFα,I L - 6 ,I L - 1 β,
and ROS, which can start to damage the pancreatic β-cells
[106–108]. IL-1β can cause extensive cytolysis in β-cells
[109] through the upregulation of iNOS and subsequent
generation of nitric oxide (NO) [110, 111], whereas TNFα
enhances IL-1β-mediated islet destruction and helps activate
APCs and T cells [112–114], but does not cause direct β-cell
apoptosis in vivo [114].
ROS and cytokines released by APCs not only promote
β-cell damage, but also help to generate an adaptive immune
response, which in T1D, is the crucial step in autoimmune
destruction. It is well established that chronic elicitation of
antigenstoinnateimmunecellsinahighlyoxidizedenviron-
ment will lead to MHC-peptide presentation, perpetuating
an adaptive immune response [115, 116]( Figure 1).
In the context of continuous β-cell ablation, macro-
phages can phagocytose dying cells and migrate to the
pancreaticlymphnodewheretheyinteractwithna¨ ıveT-cells.
It is this aforementioned synapse that enables T-cell prolifer-
ation and eﬀector function to occur. In the presence of all
three necessary signals: (1) MHC-peptide, (2) costimulation,
and(3)solublethirdsignal,inthiscaseconsistingofROS,IL-
1β,a n dT N F α, T cellsbecome activatedvia NFAT and NF-κB
[117–121]. Furthermore, IL-12 released from macrophages
candiﬀerentiateCD4+ TcellsintotheTH1lineageviasignal-
ingthroughSTAT4[122–125].CD4+ TH1cellsthenhometo
the site of antigen production, the β-cells, and call in other T
cellsandmoreAPCsthroughthesecretionofIFNγ.IFNγ has
some indirect eﬀects on β-cells, including potentiating the
maturationofpancreaticAPCs,whichcanthenelicitaneven
greater T-cell response [126]. Additionally, neutralization of
IFNγ in NOD mice has been shown to reduce both diabetes
and insulitis [127], whereas IFNγR-deﬁcient NOD mice
demonstratedelayedinsulitis,butdonotdevelopT1D[128].
Proinﬂammatory cytokines TNFα,I L - 1 β,a n dI F N γ all play a
role in β-cell death primarily through activation of redox-
regulated transcription factors NF-κBa n dS T A T 1[ 129–131].
Combinations of TNFα with IFNγ or IL-1β are necessary
for primary murine β-cell death [132], and TNFα/IFNγ act
synergistically to activate the stress-activated proapoptotic
JNK/SAPKpathway,whichpromotesβ-cellapoptosisviap53
and intracellular ROS [133]. The activation of NF-κBc a n4 Clinical and Developmental Immunology
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Figure 1:Roleofredoxintheimmunopathology oftype1diabetes.Aninitialgenetic orenvironmentalinsulttothebetacelltriggerstherelease
of beta cell antigens as well as the production of ROS. Beta cell antigens are phagocytosed, and ROS are able to stimulate redox-dependent
transcription factors such as NF-κB, which leads to APC activation and cytokine secretion. ROS and proinﬂammatory cytokines secreted by
APCs act as the third signal within the T-cell-APC immunological synapse, which occurs in the pancreatic lymph node. ROS play a critical
role in the progression of na¨ ıve TH0 cells to cytokine-secreting TH1 cells. Release of IFNγ by TH1 cells then works directly on the beta cells
as well as activates more APCs and CD8 cells, all of which can impart deleterious eﬀects on the islets.
also increase iNOS and Fas expression, potential inducers of
celldeath,whiledownregulatingtheantiapoptoticBcl-2gene
[134]. Apoptosis of β-cells is also mediated partially by T-cell
expressionofFasligand,TNFα,andperforin/granzyme[114,
134]. Speciﬁcally, CD4+ T cells are thought to be suﬃcient
for T1D onset [135, 136], whereas CD8+ T cells seem to play
a lesser role in the ﬁnal stage of autoimmune destruction
[137]. It is known, however, that synergy between both CD4
and CD8 T cells results in absolute transfer of diabetes in
rodent models [138, 139]. Although speciﬁc to the model
of autoimmune diabetes, TNFα secretion from CD4+ T
cells can activate TNFR1 on β-cells and cause apoptosis
[140], while CD8+ T cells can kill NOD β-cells by a Fas-
dependent mechanism [141] or by perforin release [142].
Ultimately, T-cell exacerbation of β-cell death comes from
endogenous generation of ROS and cytokines following APC
activation[143]thatcanperpetuateisletdestructionthrough
a feed forward mechanism. Overall, ROS are crucial in not
only activating the initial inﬁltrating macrophages and DCs
[144] via the common denominator NF-κB, but also for
subsequently driving an adaptive TH1 immune response
that is necessary for total ablation of β-cells and progression
to T1D [134, 136]. Therefore, therapies would be most
beneﬁcial if there was not only protection of the β-cells from
ROS, but also inhibition of the ROS-mediated autoimmune
attack, possibly by preventing NF-κB activation, ensuing
inﬂammation, and the initiation of the adaptive immune
response.
5.ControllingRedoxinT1D
Glutathione peroxidase (GPX), superoxide dismutase
(SOD), and catalase are categorized as the most crucial
antioxidant enzymes; however, islets inherently contain only
a fraction of the enzymatic activities in comparison to liver,
which possesses the highest abundance [145]. Because of
the low antioxidant defenses present in pancreatic islets,
therapeutic strategies to enhance antioxidants and reducing
capabilities are of utmost importance. Studies utilizing
overexpression of GPX1, SOD1 (Cu/Zn SOD), SOD2
(MnSOD), or SOD mimetic administration in insulinoma
cell lines such as NIT-1 and INS-1 aﬀorded protection from
ROS and reactive nitrogen species (RNS) in vitro [25, 146,
147]. Usage of SOD mimetics in other inﬂammatory models
has also demonstrated diminutions in proinﬂammatory
cytokines [148, 149]. Furthermore, stable transfection ofClinical and Developmental Immunology 5
insulin-producing RINm5F cells with GPX, catalase, and
Cu/Zn SOD resulted in defenses against cytokine toxicity
imparted by the combination of IL-1β,T N F α,a n dI F N γ
[150]. Antioxidant overexpression has been linked to not
only protection against ROS and cytokines, but also to
enhanced cell proliferation and decreased death. PDX1,
a transcription factor necessary for β-cell diﬀerentiation,
survival, and insulin synthesis [151], is also very responsive
to ROS [152], where high oxidation causes a cytoplasmic
relocationofPDX1outofthenucleus,increaseddegradation
of the protein, and subsequent dysfunction of β-cells [153,
154]. By alleviating ROS within the islets, PDX1 protein has
exhibited stability and enhanced function in type 2 diabetes
models [155], which can also have implications in T1D for
stabilizing β-cell function and survival. Other experiments
utilize transgene or adenoviral technology to overexpress
antioxidant genes within the β-cells to speciﬁcally show
islet-mediated versus autoimmune protection from T1D.
These studies have elicited conﬂicting results. For example,
overexpression of metallothionein and catalase in β-cells was
unable to delay or inhibit spontaneous diabetes onset within
NOD mice and promoted reduced activation of the PDX1
survival pathway [156]. Metallothionein proteins are intra-
cellular, cysteine-rich molecules with high redox potential
[157]. Similarly, transgenic expression of extracellular SOD
in β-cells does not confer any diﬀerence in T1D incidence
in comparison to control NOD mice [158]. These results
suggest that basal levels of ROS production are necessary for
β-cell function, possibly by triggering appropriate insulin
signaling and regulating cell survival [159]. In contrast,
overexpression of thioredoxin, a redox-regulated protein
which helps repair ROS-damaged proteins and DNA,
constitutes protection of β-cells from autoimmune and STZ-
induced diabetes [160]. β-cell-speciﬁc transgenic expression
of catalase and metallothionein is also able to shield isolated
islets from hydrogen peroxide and reduce the eﬀects of
STZ treatment [161–163]. Transgenic expression of heme
oxygenase-1, which has crucial cytoprotective functions
against oxidative stress and inﬂammation, can improve
insulitis and spontaneous diabetes in NOD mice [164],
and alloxan-induced diabetes is also reduced following
overexpression of Cu/Zn SOD in β-cells [165]. Moreso,
precedence for the importance of enhancing islet-associated
antioxidant levels has been demonstrated at the genetic level,
in which mice resistant to alloxan treatment (ALR mice)
exhibit protection from diabetes [94, 166]. This ﬁnding
particularly helps further justify the need for therapeutic
discovery and necessary experiments to determine druggable
targets based upon modulation of antioxidant function.
Systemic administration of antioxidants, in comparison
to overexpression studies, shows more consistency in ame-
liorating T1D. Administration of 16mg/kg/day of a potent
antioxidant to young NOD mice resulted in a reduction
of diabetes incidence from 89% in controls to 44% in the
treated animals [167]. Furthermore, after a multiple low
dose administration of STZ, addition of zinc sulphate to
the drinking water of animals was able to increase metal-
lothionein levels, inhibiting the onset of T1D [168], whereas
intraperitonealinjectionsofbutylatedhydroxyanisole(BHA)
antioxidant were able to attenuate the production of proin-
ﬂammatory cytokines by islets and macrophages, thereby
lowering insulitis and hyperglycemia [169]. Such uniformity
in these results versus the transgenic expression of multiple
antioxidants, as discussed above, may relate to the ability of
systemic therapies to not only protect the β-cells but to also
inhibit immune system activation and inﬂammation. Ade-
noviral delivery of systemic heme oxygenase to NOD mice
decreased insulitis and T1D incidence; however, this allevia-
tion was associated with a decrease in mature DCs and TH1
eﬀector function [170]. Additionally, ALR mice resistant to
alloxan-induced diabetes contain speciﬁc genetic modiﬁca-
tions conferring systemic elevation of antioxidants, resulting
in neutrophils with reduced superoxide bursts [171]. In an
in vitro system using the antioxidant probucol, which can
delay alloxan-induced [172] and spontaneous diabetes in
rats [173], macrophages exhibit decreased H2O2 production,
thus maintaining islet viability [174]. Further reports on
the eﬀects of systemic antioxidants on innate immunity
include studies from our lab utilizing metalloporphyrin-
based catalytic antioxidants (CA) with bone marrow-derived
macrophages. The CA houses a metal center that catalyzes
superoxide dismutation, mimicking SOD activity [175, 176],
and is able to scavenge a broad range of ROS including
O2
−,H 2O2,O N O O −, and lipid peroxyl radicals [53, 177,
178]. Following treatment with CA and LPS stimulation of
macrophages, the production of nitrite (NO2
−), O2
− TNFα,
andIL-1β wassigniﬁcantlyreducedincomparisontocontrol
[25, 53]. This eﬀect was mediated by the ability of CA to oxi-
dize the p50 subunit of NF-κB within the nucleus, inhibiting
its binding to DNA and subsequent transcription of proin-
ﬂammatory cytokines [53]. Redox modulation of transcrip-
tion factor DNA binding has previously been demonstrated
for NF-κBa sw e l la so t h e re u k a r y o t i cm o l e c u l e s[ 179, 180].
Inhibition of NF-κB has been well established as an eﬀective
method of thwarting the immune response and resolving
inﬂammation to maintain β-cell integrity [181, 182]; how-
ever, we are the ﬁrst to illustrate a link between metallopor-
phyrin catalytic antioxidants, blockade of NF-κB activation,
and delayed autoimmune diabetes, as described below.
The activation of macrophages and T cells relies on
oxidative stress, which ultimately leads to the progression
of T1D. Based upon this fact, CA was also investigated in
the context of CD4 and CD8 T cells. The BDC-2.5 TCR-
Tg TH1 cell clone, which has recently been described as
speciﬁc for the protein ChgA, a member of the granin
family of neuroendocrine secretory proteins [183], causes
rapid transfer of diabetes into NOD.scid recipients [184]. By
utilizing this method, pretreatment of NOD.scid mice with
CA prior to adoptive transfer of the BDC-2.5 clone inhibits
the inﬁltration of T cells into the pancreas, signiﬁcantly
delaying T1D onset. Moreover, APC-dependent BDC-2.5
Tc e l lp r o l i f e r a t i o na n dI F N γ production are also reduced
after in vitro CA treatment [25]. To further delineate
the mechanism of diminished T-cell eﬀector function,
in vivo treatment of NOD and BDC-2.5 TCR-Tg mice
with CA was able to decrease innate-derived third signal
synthesis, primarily consisting of TNFα, resulting inantigen-
speciﬁc T cell hyporesponsiveness [37]. Similar results were6 Clinical and Developmental Immunology
found upon CA treatment in the context of CD8 T cells,
reducing proliferation, cytokine production, and cytolytic
eﬀector molecules of CTLs [185]. Interestingly, by inhibiting
NADPHoxidaseinNODanimals(NOD.Ncf1m1J)inaneﬀort
to genetically mimic systemic CA administration, not only is
NOX-derived superoxide production eliminated, but T cells
show reduced TH1 responses, granting protection from T1D
onset [120]. Earlier studies by Chaudhri et al. supported
our experimentation by demonstrating attenuation of T-
cell proliferation and IL-2R expression following antioxidant
treatment [186, 187]. Such ﬁndings point to the possibility
and importance of redox modulation in not only regulating
the innate immune cells, but also impacting the T cells
which formulate an adaptive immune response crucial for
the autoimmune attack in T1D (Figure 2).
In addition to decreasing oxidative stress imposed on
the islets, which can directly damage β-cells or indirectly
stimulate the autoreactive immune response to become acti-
vated, redox modulation may also be useful for decreasing
the unyielding ER stress within the β-cells. Because the β-
cells are a constant source of insulin and insulin must be
folded properly for secretion, the importance of balancing a
high protein-folding load with survival of the cells increases
substantially in comparison to other nonsecretory cells
[188]. An overload of misfolded proteins may eventually
result in cell death, if not properly resolved. An early study
by Lo et al. highlighted the susceptibility of β-cells to ER
stress by overexpressing MHC class II proteins in islets,
essentially overwhelming the protein folding machinery
and leading to apoptosis [189]. Other more recent studies
show biochemical connections between ER stress-induced
apoptosis and β-cell death, through both calcium-dependent
and independent molecules [190–192]. To reconcile protein
misfolding within the ER, the unfolded protein response, or
UPR, is consequently triggered [193, 194]. The UPR acts
as a backup mechanism to protect cells from accumulating
unfolded proteins and to restore the balance between the
protein folding machinery and the secretory pathway [195].
However, an accumulation of unfolded proteins during
severe ER stress is sometimes unable to be resolved by the
UPR, as characterized in the Akita mouse which contains
a mutation in the proinsulin 2 gene that disrupts insulin
folding, retains it within the ER, activates UPR, yet still
eventually leads to β-cell death [196, 197]. Moreover, ROS
have been suggested in supporting the UPR towards a more
proapoptotic than proadaptive level [198], further illustrat-
ing the importance of regulating oxidative stress to maintain
β-cell survival. Although the UPR paradoxically utilizes
an oxidative environment within the ER to correctly fold
proteins (i.e., disulﬁde bond formation), sustained oxidative
stress can perpetuate the UPR to a level that promotes apop-
tosis [198, 199]. Additionally, the abundance of ROS present
during continued unadapted ER stress can trigger apoptosis
in neighboring cells as well. This is especially critical in islet
β-cells,wheretheirabilitytohandleoxidativestressisalready
reduced because of low levels of antioxidants [24, 82–84].
More pertinent is when unresolved ER stress leads to dying
β-cells containing the misfolded proteins. These cells can
be taken up by resident pancreatic APCs and presented
to autoreactive T cells within the pancreatic lymph nodes.
This type of event may stimulate the reactivity of T cells to
formerly tolerated “neo-autoantigens,” which can ultimately
promote more β-cell destruction and eventual development
of autoimmune diabetes [200, 201]. A study conducted by
Malhotra, et al. shows that antioxidant treatment of CHO
cells results in not only decreased oxidative stress, but also
decreasedmisfoldedproteins,reducedactivationoftheUPR,
and enhanced secretion of proteins [188]. Thus, it appears
that a temporal or redox balance is essential for optimal β-
cell function. In situations where the β-cell may experience
environmental stressors that lead to disruption of the ER-
machinery, the results may set in motion both ER-stress-
induced UPR and the expression of misfolded proteins in
an oxidative environment, further providing an optimal
milieu for driving autoreactive T cells to become activated.
Therefore, redox modulation may serve yet another purpose:
to help reduce ER stress and subsequently maintain β-cell
viability.
Although the ability to predict susceptibility to type
1 diabetes is becoming increasingly accurate [202], and
therefore, prophylactic treatment of patients with antioxi-
dant therapeutics is not out of the realm of possibilities,
currently a more feasible option for individuals with chronic
hyperglycemia is to undergo islet transplantation. Islets, like
any other transplantable organ, are in short supply; however,
maintaining function and viability of transplanted islets is
the major drawback of the procedure [161]. Not only are
islets susceptible to immune rejection, but hypoxia during
isolation and transplantation is the primary cause of β-cell
death [203]. Because of their low resistance to ROS [24, 82–
84], β-cells are especially vulnerable to oxidative damage
and ischemia-reperfusion injury [204, 205]. In order to
combat this weakness, the application of antioxidants seems
asuitablealternative,astheyhaveshownpromiseinliverand
kidney transplantations [206, 207]. Longer allograft survival
times have been demonstrated with mouse islets soaked
with hydroxyl-radical inhibitors prior to transplantation
[208] and with multiple in vivo administrations of SOD
and catalase prior to and after islet transplantation [209].
Likewise, transduction of islets with heme oxygenase-1 or
SOD2 genes was able to improve viability and insulin
secretion in vitro [210] and elicit greater functionality
upon transplantation in comparison to controls [211],
respectively.Furthermore,wehavealsodemonstratedbeneﬁt
using the catalytic antioxidant approach, whereby adding
CA during and after human islet isolation enhanced cell
survival and function, allowing for normalization of STZ-
induced diabetic NOD.scid mice [212]. Additionally, CA is
not only able to protect human islets from STZ cell damage,
but can also protect murine islets from both antigen-
independent innate-mediated inﬂammation and antigen-
dependent T-cell-mediated allograft rejection [204]. Overall,
unlike common antirejection drugs, which are outstanding
at protecting against the adaptive immune response but
fail to shield islets from ROS/inﬂammation [213, 214],
our CA treatment is nontoxic to islets and can alleviateClinical and Developmental Immunology 7
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Figure 2: Role of redox modulation in controlling ROS-mediated beta cell destruction. Redox modulation has shown promise in blocking the
production of ROS and its ability to activate APCs, resulting in diminished TH1 cell activation and eﬀector function, which ultimately may
help regulate beta-cell destruction.
both the alloimmune [204] and autoimmune responses
[25, 37, 53, 185].
6. Conclusion
Although redox has been extensively studied in the context
of both T1D and type 2 diabetes [85, 215], the plethora
of literature discussed above shows the implications of
ROS in all stages of autoimmune T1D, including the
primary “trigger”, the initiation of insulitis by the innate
immune system, and the acquisition of T-cell-mediated
autoreactivity. These studies open the door to novel ideas
of redox modulation, such as targeting ROS-dependent
immunological metalloproteases [43, 44, 49] or disrupting
the autoreactive T-cell pool, as described [37, 120, 185].
Moreover, a study evaluating self-antigen-primed T cells
demonstrates how NO is able to reduce FOXP3 expression
and subsequently decrease Tregs in autoimmune disorders
[216], illustrating how intricate and vast the role of redox
is in the immune response and where future studies may
focus. In addition to eﬀects on the target organ(s) and the
immune system, autoimmunity also gives rise to systemic
problems, and in the context of diabetes, ROS have been
characterized as crucial elements promoting hyperglycemia-
induced diabetic complications, especially those involving
the vasculature [6, 217]. One important study conducted by
Ling et al. provided evidence of oxidative stress-mediated
vascular complications in prediabetic NOD mice [218],
which exempliﬁes the importance of ROS in not only
exacerbation of disease, but also on initiation of T1D and
nonhyperglycemic associated pathologies. Furthermore, uti-
lizing antioxidants, such as Vitamin E, cannot only assuage
vascular activation [219], but can also grant protection from
the loss of secondary target organ function, such as the
kidneys [220]. Therefore, oxidative stress aﬀects every aspect
of T1D and the beneﬁt of redox modulation may be more
important than once thought. Optimal treatments may have
to incorporate antioxidants with anti-inﬂammatory agents,
such as inhibitors of NF-κB activation, and must also take
into consideration the limitations associated with utilization
of intact enzyme/protein therapies, including bioavailability,
immunogenicity-limited cellular accessibility, and cost of
production. However, with the advent of newer nonpep-
tidyl small compounds, alleviating oxidative stress through
antioxidant therapy appears to be a plausible druggable
target. This therapy should restore balance between oxida-
tion and reduction, leading to resolution of inﬂammation,
thus reducing the autoimmune destruction of the islet
β-cells.8 Clinical and Developmental Immunology
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